Global Urological Disorders Treatment Market – Introduction
The
urinary tract is a drainage system of the human body, which is meant
for urine removal. The urinary tract includes the ureters, the kidneys,
and the urinary bladder. Urologic conditions or diseases include kidney
stones, prostate issues, urinary tract infections, and bladder control
issues. Certain urological disorders last only for a short time, while
others last for a long time. Urological disorders are highly prevalent
and widespread. They have been reported throughout the globe. They make
an impact on the lives of millions of individuals causing severe
influence on their emotional and physical health. This disease affects
females more than males and its incidence increases with age.
Report Overview @ https://www.transparencymarketresearch.com/urological-disorders-treatment-market.html
Global Urological Disorders Treatment Market – Competition Landscape
Boston Scientific Corporation
Founded
in 1976, Boston Scientific Corporation develops, manufactures, and
markets medical devices worldwide for use in multiple medical
intervention specialties. It operates through three segments: MedSurg,
Rhythm & Neuro, and Cardiovascular. Boston Scientific partners with
urologists to continuously promote quality of patient care with
innovative alternatives for urology. The company offers a wide range of
treatment options for urological disorders such as stone management,
benign prostatic hyperplasia (BPH) management, erectile restoration, and
male continence.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
Sanofi
Incorporated
in 1999, Sanofi-Aventis US LLC, a subsidiary of Sanofi, offers products
for insulin pens. Sanofi-Aventis US LLC engages in the research,
development, manufacture, and marketing of products for cardiovascular
diseases, cancer, diabetes, and rare diseases. The company offers
branded drugs, such as Libtayo, Jevtana, and Taxotere, for treatment of
urological disorders.
Astellas Pharma Inc.
Established
in 2005, Astellas Pharma Inc. is a Japan-based company primarily
engaged in the research, development, manufacture, and sale of
pharmaceutical products. The company is involved in the manufacture and
sale of pharmaceutical products in Japan, the U.S., Europe, China, South
Korea, Taiwan, and other markets through its subsidiaries. Its key
products include an immunosuppressive drug called Prograf, an overactive
bladder agent called Vesicare, an ointment for atopic dermatitis called
Protopic, Harnal, a product for prostatic and urethral smooth muscles,
and an antimycotic agent called Funguard.
Key
players operating in the global urological disorders treatment market
include Boston Scientific Corporation, Sanofi, Astellas Pharma Inc.
Johnson & Johnson (Janssen Global Services, LLC), Pfizer Inc.,
ALLERGAN, Abbott, Merck & Co., Inc., Takeda Pharmaceutical Company
Limited, Becton, Dickinson and Company, Intuitive Surgical, KARL STORZ
SE &Co. KG, Richard Wolf GmbH, Fresenius Medical Care, Cook Medical,
Olympus Corporation, Siemens Healthineers, Stryker, Braun Melsungen AG,
Baxter International Inc., and Medtronic.
Expanding operations in future? To get the perfect launch ask for a custom report here
Global Urological Disorders Treatment Market – Dynamics
Increase in demand for minimally invasive products across the globe to propel global urological disorders treatment market
Presence
of a large pool of patients with urinary illnesses and other symptoms
is anticipated to drive the global urology disorders treatment during
the forecast period. This high growth rate of the market is attributable
to rise in the adoption of urological devices, easy availability of
urological devices, and increased demand for minimally invasive products
throughout the globe.
Increasing prevalence of urinary tract infections to boost global urological disorders treatment market
Urinary
tract infections (UTIs) are the most common bacterial infections that
affect both young and old individuals. This infection generally affects
one or more parts of the urinary system and it is especially prevalent
among women, with the rate of prevalence of about 1% among college-going
girls and 4% among women in child-bearing age. Moreover, developing
healthcare infrastructure in nations with high growth potential,
increasing healthcare spending per capita, and rise in the number of
patients suffering from urological disorders every year are major
factors projected to drive the global urological disorders treatment
market from 2019 to 2027.
No comments:
Post a Comment